Added 5 November 2026. The source paper was published on 2 June 2026. These are new catalog additions.
DCA0006
LC-MG-1 is an infigratinib-derived research compound with an E-configured phenyl enone handle. It was identified as an initial FGFR2-degradation hit in KATO III cells at 1 µM for 12 h and used as the starting scaffold for the phenyl-handle structure–activity study.
Evidence and quotation →
DCA0007
LC-MG-4 is an infigratinib-derived research compound bearing an unsubstituted acrylamide handle. The paper reports moderate FGFR2 degradation in KATO III cells at 1 µM for 12 h. It served as the reference scaffold for testing changes to the Michael-acceptor group.
Evidence and quotation →
DCA0008
LC-MG-9 is the para-methyl phenyl analogue of LC-MG-1 in an infigratinib-derived FGFR2-degradation series. In the same KATO III Western-blot screen at 1 µM for 12 h, its FGFR2-depletion effect was weaker than that of LC-MG-1. It is a comparative research compound for phenyl-handle structure–activity studies.
Evidence and quotation →